Heparin ( DrugBank: Heparin )


12 diseases
告示番号疾患名(ページ内リンク)臨床試験数
47バージャー病1
60再生不良性貧血1
70広範脊柱管狭窄症1
79家族性高コレステロール血症(ホモ接合体)1
84サルコイドーシス1
107若年性特発性関節炎1
224紫斑病性腎炎1
226間質性膀胱炎(ハンナ型)8
280巨大動静脈奇形(頚部顔面又は四肢病変)1
299嚢胞性線維症4
316カルニチン回路異常症1
317三頭酵素欠損症1

47. バージャー病


臨床試験数 : 9 薬物数 : 13 - (DrugBank : 7) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 15
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2100048104
2021-08-012021-07-01A clinical study of safety and efficacy of transcatheter intra-arterial infusion of extract of Ginkgo biloba leaves injection in the treatment of sever limb ischemia in patients with Thromboangiitis ObliteransA clinical study of safety and efficacy of transcatheter intra-arterial infusion of extract of Ginkgo biloba leaves injection in the treatment of sever limb ischemia in patients with Thromboangiitis Obliterans Thromboangiitis ObliteransTreatment group:Transcatheter intra-arterial infusion of Ginkgo biloba leaves injection;Control group:Transcatheter intra-arterial infusion of heparin sodium injection;First Clinical Center of Chinese PLA General HospitalNULLPending50BothTreatment group:30;Control group:30;China

60. 再生不良性貧血


臨床試験数 : 235 薬物数 : 381 - (DrugBank : 83) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 160
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01343680
(ClinicalTrials.gov)
April 201127/4/2011Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology PatientsA Randomized Controlled Crossover Trial of Two Different Central Venous Catheter Flushing Schemes in Pediatric Hematology and Oncology Patients in Alberta, CanadaChildhood Cancer;Aplastic Anemia;Metabolic DisordersDrug: Heparin;Drug: Normal salineAlberta Children's HospitalStollery Children's HospitalTerminatedN/A17 YearsBoth2Phase 3Canada

70. 広範脊柱管狭窄症


臨床試験数 : 96 薬物数 : 203 - (DrugBank : 60) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 89
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01522846
(ClinicalTrials.gov)
January 20129/1/2012Heparin Solution and INTEM/HEPTEM AnalysisInfluence by Heparinized Flush Solution of the Radial Artery Catheter: INTEM and HEPTEM Analysis.Brain Tumor;Spinal Stenosis;Cerebral Artery AnuerysmDrug: HeparinSeoul National University Bundang HospitalNULLCompleted20 YearsN/ABoth25N/AKorea, Republic of

79. 家族性高コレステロール血症(ホモ接合体)


臨床試験数 : 142 薬物数 : 114 - (DrugBank : 29) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 18
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02286596
(ClinicalTrials.gov)
April 20133/11/2014Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial HypercholesterolemiaComparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial HypercholesterolemiaHomozygous Familial HypercholesterolemiaDevice: heparin-induced extracorporeal LDL precipitation;Device: dextran sulfate adsorptionLaval UniversityNULLCompleted18 Years60 YearsBoth9N/ACanada

84. サルコイドーシス


臨床試験数 : 149 薬物数 : 227 - (DrugBank : 81) / 標的遺伝子数 : 82 - 標的パスウェイ数 : 167
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000004267
2010/10/0101/10/2010PET/CT finding of cardiac sarcoidosis sarcoidosisGive heparin Na before 18F-FDG PET/CT in the diagnosis of cardial sarcoidosis.Tokushima University HospitalNULLPendingNot applicableNot applicableMale and Female30Not selectedJapan

107. 若年性特発性関節炎


臨床試験数 : 441 薬物数 : 282 - (DrugBank : 56) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 142
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-OOC-15006228
2015-04-012015-04-09Clinical and mechanism research of extracellular histone in systemic-onset juvenile idiopathic arthritisClinical and mechanism research of extracellular histone in systemic-onset juvenile idiopathic arthritis systemic-onset juvenile idiopathic arthritisdisease active group,disease remission group:add heparin into neutrophils in vitro;Shanghai Children's Medical CenterNULLRecruiting316Bothdisease active group,disease remission group:30;China

224. 紫斑病性腎炎


臨床試験数 : 13 薬物数 : 42 - (DrugBank : 20) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 57
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03591471
(ClinicalTrials.gov)
September 20149/12/2014Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep TreatmentDemonstrated Study on Children Henoch-Schönlein Purpura Nephritis With Multistep Treatment of Traditional Chinese Medicine Combined Disease and Syndrome DifferentiationHenoch-Schönlein Purpura NephritisDrug: Glycosides Of Tripterygium Wilfordii Hook(GTW);Drug: Sulfotanshinone Sodium Injection;Drug: Chinese herbs based on syndrome differentiation;Drug: Prednisone Acetate Tablets;Drug: Benazepril Hydrochloride Tablets;Drug: Low Molecular Weight Heparin Calcium Injection;Drug: Dipyridamole Tab 25 MG;Drug: Chinese medicine placeboHenan University of Traditional Chinese MedicinePeking University First Hospital;Children's Hospital of Fudan University;Shanghai Children's Hospital;Chengdu University of Traditional Chinese Medicine;Affiliated Hospital of Yunnan University of Traditional Chinese MedicineUnknown status2 Years18 YearsAll500Phase 1/Phase 2China

226. 間質性膀胱炎(ハンナ型)


臨床試験数 : 143 薬物数 : 171 - (DrugBank : 56) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 145
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04401176
(ClinicalTrials.gov)
September 15, 202019/5/2020Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain SyndromeA Randomized Trial of Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain SyndromeInterstitial Cystitis;Bladder Pain SyndromeDrug: Heparin & Alkalinized Lidocaine Bladder Instillation;Drug: Onabotulinum Toxin AWalter Reed National Military Medical CenterNULLRecruiting18 YearsN/AFemale58Phase 2United States
2JPRN-UMIN000027918
2016/07/0125/06/2017Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitis interstitial cystitisheparin-lidocaine intravesical therapyDepartment of Urology and Renal transplantation, Nagasaki University HospitalNULLRecruiting20years-old80years-oldMale and Female30Not selectedJapan
3JPRN-UMIN000026714
2016/02/2627/03/2017RCT study of bladder instillation therapy in patients with refractory interstitial cystitis. Interstitial cystitisTreated with vesical instillation with heparin and alkalized lidocaine. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation.
Treated with vesical instillation with heparin alone. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation.
Department of Urology, Mitsui Memorial HospitalNULLPending20years-oldNot applicableMale and Female20Phase 2,3Japan
4NCT02591199
(ClinicalTrials.gov)
September 201528/10/2015Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain SyndromeA Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain SyndromeInterstitial Cystitis;Bladder Pain SyndromeDrug: URG101;Drug: Placebo;Drug: Lidocaine;Drug: HeparinUrigenNULLTerminated18 YearsN/AAll92Phase 2United States
5NCT01048177
(ClinicalTrials.gov)
December 201211/1/2010A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized VulvodyniaA Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized VulvodyniaVulvodyniaDrug: Bladder instillation with heparin/ lidocaineScripps HealthNULLWithdrawn18 Years80 YearsFemale0Phase 2United States
6JPRN-UMIN000006387
2011/11/0131/10/2011Clinical study on the intravesical instillation of heparin, lidocain and bicarbonate for the patients with interstitial cystitis interstitital cystitisIntravesical instillation of heparin, lidocain and bicarbonateUniversity of TokushimaNULLPendingNot applicableNot applicableMale and Female30Phase 2Japan
7NCT05223244
(ClinicalTrials.gov)
October 1, 201124/1/2022Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed ICBladder Capacity as an Objective Measure of Response to Intravesical Treatment of Newly Diagnosed Interstitial Cystitis: a Prospective, Randomized TrialInterstitial Cystitis;Painful Bladder SyndromeDrug: bupivacaine, triamcinolone, and heparin (BTH);Drug: dimethyl sulfoxide (DMSO)NorthShore University HealthSystemNULLCompleted18 YearsN/AFemale83Phase 4NULL
8NCT00256542
(ClinicalTrials.gov)
January 200617/11/2005Study of U101 for Bladder Pain and/or UrgencyA Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder OriginPelvic Pain;Interstitial Cystitis;Bladder DiseasesDrug: Alkalinized Lidocaine-HeparinUrigenNULLCompleted18 YearsN/ABoth90Phase 2United States

280. 巨大動静脈奇形(頚部顔面又は四肢病変)


臨床試験数 : 25 薬物数 : 29 - (DrugBank : 15) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 153
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03306836
(ClinicalTrials.gov)
September 201631/5/2017Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2Multi-center,Single Blind,Prospective Randomized Controlled Trial of Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid OperationCerebral Aneurysm;Arteriovenous MalformationsDrug: Heparin SodiumBeijing Tiantan HospitalTang-Du Hospital;Kunming Medical University;First Affiliated Hospital of Fujian Medical University;Nanjing PLA General Hospital;Fujian Medical University Union HospitalRecruitingN/A70 YearsAll408N/AChina

299. 嚢胞性線維症


臨床試験数 : 1,696 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-006276-11-IT
(EUCTR)
18/05/201007/05/2010A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - NDA Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - ND Cystic Fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011763
Product Name: heparin 25mg inhalation powder, hard capsule
Product Code: VR496
VECTURA LIMITEDNULLNot RecruitingFemale: yes
Male: yes
64Phase 1/2Ireland;Italy
2EUCTR2007-006276-11-IE
(EUCTR)
11/11/200811/02/2008A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in adults with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in adults with Cystic FibrosisA Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in adults with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in adults with Cystic Fibrosis Cystic Fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
Product Name: Heparin 25mg inhalation powder, hard capsule
INN or Proposed INN: HEPARIN SODIUM
Vectura LimitedNULLNot RecruitingFemale: yes
Male: yes
64Phase 1/2Ireland;Italy
3EUCTR2007-006276-11-GB
(EUCTR)
01/09/200826/11/2007A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in patients with Cystic FibrosisA Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in patients with Cystic Fibrosis Cystic Fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
Product Name: Heparin 25mg inhalation powder, hard capsule
INN or Proposed INN: HEPARIN SODIUM
Vectura LimitedNULLNot RecruitingFemale: yes
Male: yes
64Phase 1/2Ireland;Italy;United Kingdom
4EUCTR2007-006276-11-PL
(EUCTR)
06/05/2009A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in patients with Cystic FibrosisA Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496/005- Orally inhaled heparin in patients with Cystic Fibrosis Cystic Fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
Product Name: Heparin 25mg inhalation powder, hard capsule
INN or Proposed INN: HEPARIN SODIUM
Vectura LimitedNULLNot RecruitingFemale: yes
Male: yes
64Phase 2Poland;Ireland;Italy;United Kingdom

316. カルニチン回路異常症


臨床試験数 : 4 薬物数 : 10 - (DrugBank : 4) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 11
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02517307
(ClinicalTrials.gov)
February 20162/7/2015Fatty Acid Oxidation Defects and Insulin SensitivityRole of Fatty Acid Oxidation Defects in Insulin SensitivityVery Long-chain Acyl-CoA Dehydrogenase Deficiency;Trifunctional Protein Deficiency;Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency;Medium-chain Acyl-CoA Dehydrogenase Deficiency;Normal Volunteers;Carnitine Palmitoyltransferase II Deficiency, MyopathicDrug: Intralipid/Heparin;Drug: Glycerol/Saline;Drug: Hyperinsulinemic euglycemic clampOregon Health and Science UniversityNULLCompleted18 YearsN/AAll52N/AUnited States

317. 三頭酵素欠損症


臨床試験数 : 3 薬物数 : 8 - (DrugBank : 4) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 1
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02517307
(ClinicalTrials.gov)
February 20162/7/2015Fatty Acid Oxidation Defects and Insulin SensitivityRole of Fatty Acid Oxidation Defects in Insulin SensitivityVery Long-chain Acyl-CoA Dehydrogenase Deficiency;Trifunctional Protein Deficiency;Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency;Medium-chain Acyl-CoA Dehydrogenase Deficiency;Normal Volunteers;Carnitine Palmitoyltransferase II Deficiency, MyopathicDrug: Intralipid/Heparin;Drug: Glycerol/Saline;Drug: Hyperinsulinemic euglycemic clampOregon Health and Science UniversityNULLCompleted18 YearsN/AAll52N/AUnited States